SYNOPSIS

At the 2024 Precision Health Information Network Summit—its seventh gathering and the first under a new name—leaders from across the healthcare ecosystem convened in Nashville to chart the future of diagnostics-informed medicine. Sessions explored the economic, regulatory, and technological shifts reshaping diagnostics, while spotlighting persistent challenges in rare disease navigation, women’s health disparities, and oncology implementation. A new pre-meeting format deepened collaboration around clinical decision support and biomarker testing. Throughout the Summit, participants emphasized real-world obstacles and solution-driven case studies, reaffirming the event’s role as a catalyst for cross-sector progress in precision health.

Five impactful themes emerged that differentiated the discussion from previous meetings:

1. Market conditions are impacting laboratory diagnostic business models.

2. Increased FDA regulation, particularly of laboratory-developed tests, will reshape the market (with the caveat that court rulings since the Summit may prevent the new rule from going into effect)

3. While recent investments are leading to advancements in diagnostics for women's health, historical underinvestment means many conditions remain under addressed.

4. Despite technology innovation in rare disease and real-world data, widespread collaboration and data sharing for individual patient navigation is still manual, time-consuming, and burdensome.

5. Clinically valid diagnostic tests are still underutilized in oncology, and the ongoing multi-stakeholder collaboration needed to increase access and use has not yet reached critical mass.

Download the whitepaper to read more.